American Society of Hirudotherapy

Avoiding ambient air in test tubes during incubations of human whole-blood minimizes complement background activation

Methodology published in J Immunol Methods (2020)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentStorm BS et al. · Journal of immunological methods, 2020

Abstract

BACKGROUND: In vitro, the complement system can be studied in test tubes incubated with anticoagulated human whole-blood. Background activation of complement may mask inflammatory signals. Air bubbles are known to activate complement. We examined if removing ambient air from test tubes before incubation reduced background complement activation. METHODS: Blood from twelve donors was anticoagulated with the thrombin inhibitor lepirudin and incubated with either no air, ambient air or air bubbles in polypropylene tubes at 37 °C for 180 min on a roller mixer. After incubation, EDTA was added, plasma isolated and analyzed for seven complement activation products using ELISA. Results are presented as means with 95% confidence intervals. RESULTS: Blood incubated without air had significantly lower complement activation compared to blood incubated with ambient air; C4d 273 (192-364) vs. 379 (263-494) ng/mL (p = 0.002), C4bc 8.2 (4.1-13) vs. 12 (3.2-21) CAU/mL (p = 0.01), C3a 1351 (873-1838) vs. 2944 (2315-3572) ng/mL (p = 0.0005), C3bc 31 (17-46) vs. 68 (52-84) CAU/mL (p = 0.002), C3bBbP 134 (97-171) vs. 427 (358-506) CAU/mL (p < 0.0001), C5a 3.5 (1.9-5 0.2) vs. 15 (1.8-27)) ng/mL (p = 0.003), TCC 4.6 (2.8-6.3) vs. 9.9 (7.3-12) CAU/mL (p = 0.006). At the end of the experiment blood incubated with air bubbles had a higher complement activation than blood incubated with ambient air with an average 26 fold increase (range 1.6-59) from baseline of all activation products; C4d 551 (337-766) ng/mL, C4bc 21 (5.0-36) CAU/mL, C3a 3983 (3518-4448) ng/mL, C4bc 103 (86-121) CAU/mL, C3bBbP 626 (543-708) CAU/mL, C5a 10 (2.8-18) ng/mL and TCC 10 (6.0-14) CAU/mL. CONCLUSION: Avoiding air in test tubes during whole-blood experiments reduced background complement activation substantially and represents an important improvement to the lepirudin whole-blood model. This could also apply to other in vitro models.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAdultAirAntithrombinsBlood Specimen CollectionComplement ActivationComplement System ProteinsEdetic AcidEnzyme-Linked Immunosorbent AssayFemaleHirudinsHumansMaleMiddle AgedRecombinant ProteinsReproducibility of Results

Summary

In lepirudin-anticoagulated whole blood from twelve donors, excluding ambient air during incubation significantly lowered all seven complement activation products versus ambient air, improving this inflammation model; air bubbles increased activation on average 26-fold from baseline.

Why This Matters for Hirudotherapy

This study investigated whether removing ambient air from test tubes during incubation of human whole blood anticoagulated with lepirudin reduces background complement activation. Using blood from twelve donors, the authors showed significantly lower activation of seven complement products (C4d, C4bc, C3a, C3bc, C3bBbP, C5a, TCC) when air was excluded, and described this as an improvement to the lepirudin whole-blood model. The abstract refers to lepirudin only as a thrombin inhibitor used for anticoagulation and provides no information on leech biology, leech-derived substances, or hirudotherapy. No leeches, leech secretome components, or hirudotherapy interventions were studied; the work optimizes an in-vitro complement activation assay technique.

Citation

Reference (Vancouver style)

Storm BS, Christiansen D, Mollnes TE, Nielsen EW. Avoiding ambient air in test tubes during incubations of human whole-blood minimizes complement background activation. J Immunol Methods. 2020;487:112876. doi:10.1016/j.jim.2020.112876. PMID: 33031792

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.